Press-release for stocks published on this year for TAK

published : This year symbols : TAK

save search

Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.185 0.19% 430K

Health Technology

| 0.0% | O: 0.42% H: 0.0% C: 0.0%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| 0.0% | O: 0.82% H: 0.0% C: 0.0%
MIRM | $23.7 0.55% 110K

Health Technology

| 0.0% | O: 1.42% H: 0.0% C: 0.0%
report million reach treatment market

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.185 0.19% 430K

Health Technology

| 0.0% | O: 0.0% H: 0.0% C: 0.0%
entyvio fda disease active for therapy

Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors
Published: 2024-04-15 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.185 0.19% 430K

Health Technology

| -2.38% | O: -1.19% H: 0.26% C: -0.98%
company

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.185 0.19% 430K

Health Technology

| -7.07% | O: 1.84% H: 0.24% C: -0.14%
adzynma japan takeda approval injection

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.185 0.19% 430K

Health Technology

| -9.68% | O: -0.07% H: 0.0% C: -0.96%
iclusig fda drug takeda approval application

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
TAK | News | $13.185 0.19% 430K

Health Technology

| -9.68% | O: -0.07% H: 0.0% C: -0.96%
CNTG | $0.461 14K

Commercial Services

| -31.41% | O: 1.43% H: 1.41% C: -1.41%
partnership genetic takeda disorders

Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.185 0.19% 430K

Health Technology

| -8.3% | O: 0.21% H: 0.97% C: 0.7%
NVS | $93.81 1.34% 1.2M

Health Technology

| -5.15% | O: 0.05% H: 0.14% C: -0.93%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
LLY | $728.765 -2.3% 1.5M

Health Technology

| -1.31% | O: -0.7% H: 0.73% C: -0.16%
ABBV | News | $166.43 1.08% 2M

Health Technology

| -8.4% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| -6.03% | O: -0.02% H: 0.0% C: 0.0%
REGN | $894.71 0.08% 180K

Health Technology

| -6.03% | O: -0.27% H: 1.26% C: 0.84%
AMGN | $266.895 1.58% 950K

Health Technology

| -2.43% | O: 0.2% H: 1.14% C: -1.18%
antibody therapeutics market

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.185 0.19% 430K

Health Technology

| -8.49% | O: 0.21% H: 0.17% C: 0.14%
tak-079 positive topline potential results study

Alexandria Real Estate Equities, Inc. Announces Significant Early Renewal and 10-Year Lease Extension With Longstanding Credit Tenant Takeda at the Alexandria Center at Kendall Square Mega Campus in Cambridge
Published: 2024-03-04 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.185 0.19% 430K

Health Technology

| -9.68% | O: -0.69% H: 0.35% C: 0.14%
ARE A | $117.65 0.98% 180K

Finance

| -5.86% | O: -0.01% H: 1.98% C: 1.41%
extension

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.185 0.19% 430K

Health Technology

| -11.21% | O: 0.0% H: 0.47% C: 0.2%
vaccine dengue tak-003 qdenga

Plasma Therapy Global Market Report 2024 - Projected Compound Annual Growth Rate of 12.5%, with Market Set to Reach $0.88 Billion in 2028
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.185 0.19% 430K

Health Technology

| -10.79% | O: -0.2% H: 0.14% C: -0.48%
BAX | $39.545 -0.27% 690K

Health Technology

| -5.99% | O: -0.38% H: 0.14% C: -0.14%
KMDA | $5.21 2.16% 19K

Health Technology

| -15.22% | O: 2.0% H: 2.28% C: 1.63%
ADMA 4 | $6.18 -0.32% 500K

Health Technology

| 19.69% | O: 0.19% H: 2.5% C: 1.35%
report reach global set therapy growth market

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 510

Health Technology

| -5.87% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 600K

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | $138.24 800

Health Technology

| 6.54% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -8.14% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $63.676 7.2K

Manufacturing

| 25.87% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | $9.47 520K

Manufacturing

| -16.01% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.185 0.19% 430K

Health Technology

| -10.79% | O: -0.2% H: 0.14% C: -0.48%
NVS | $93.81 1.34% 1.2M

Health Technology

| -9.24% | O: -0.06% H: 0.46% C: 0.29%
GSK | $39.605 0.85% 790K

Health Technology

| -5.58% | O: -0.69% H: 1.42% C: 1.22%
LLY | $728.765 -2.3% 1.5M

Health Technology

| 0.65% | O: 2.37% H: 1.51% C: 0.79%
BMY | $48.58 0.58% 2.6M

Health Technology

| -5.13% | O: -0.65% H: 1.63% C: 1.48%
ABBV | News | $166.43 1.08% 2M

Health Technology

| -6.33% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| -3.44% | O: 1.67% H: 0.0% C: 0.0%
AZN | $68.3 -0.09% 2M

Health Technology

| 4.88% | O: -2.81% H: 2.08% C: 1.38%
AMGN | $266.895 1.58% 950K

Health Technology

| -6.54% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®
Published: 2024-02-21 (Crawled : 08:00) - prnewswire.com
TAK | News | $13.185 0.19% 430K

Health Technology

| -11.27% | O: -0.88% H: 0.34% C: 0.34%
entyvio disease biosimilar

Albumin Market to Reach $9.9 billion, Globally, by 2032 at 6.2% CAGR: Allied Market Research
Published: 2024-02-15 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.0354 320

Communications

| -1.65% | O: 3.61% H: 0.0% C: -0.13%
TMO | News | $544.01 0.46% 470K

Health Technology

| -2.79% | O: -0.18% H: 1.09% C: 0.24%
TAK | News | $13.185 0.19% 430K

Health Technology

| -9.56% | O: -0.83% H: 0.38% C: 0.0%
reach research market

Protein Inhibitors Global Market Report 2024 - A $125 Billion Market in 2028, Registering Compound Annual Growth of 9%
Published: 2024-02-14 (Crawled : 02:00) - prnewswire.com
LZAGF | $563.5 6

Health Technology

| 12.7% | O: 3.14% H: 1.92% C: 1.92%
GLAXF | $20.2 510

Health Technology

| -3.81% | O: -2.14% H: 0.0% C: -0.63%
SNYNF | News | $92.7 600K

Health Technology

| -0.29% | O: -2.71% H: 0.0% C: 0.0%
AZNCF | $138.24 800

Health Technology

| 9.56% | O: 0.87% H: 0.21% C: -2.23%
LZAGY | $55.65 32K

Professional, Scientific, and T...

| 15.41% | O: 4.07% H: 1.53% C: 1.45%
TMO | News | $544.01 0.46% 470K

Health Technology

| -1.04% | O: 0.56% H: 1.3% C: 1.22%
TAK | News | $13.185 0.19% 430K

Health Technology

| -8.3% | O: 0.42% H: 1.04% C: 0.97%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -8.08% | O: -0.91% H: 0.0% C: 0.0%
GSK | $39.605 0.85% 790K

Health Technology

| -4.32% | O: 0.89% H: 0.41% C: 0.1%
LLY | $728.765 -2.3% 1.5M

Health Technology

| 1.05% | O: 0.38% H: 2.44% C: 1.54%
BAX | $39.545 -0.27% 690K

Health Technology

| 0.2% | O: 0.33% H: 0.63% C: -0.28%
ABBV | News | $166.43 1.08% 2M

Health Technology

| -5.33% | O: -0.73% H: 0.0% C: 0.0%
ABT | News | $106.76 1.42% 3.8M

Health Technology

| -5.49% | O: -0.83% H: 0.66% C: 0.38%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| -1.43% | O: -1.1% H: 0.0% C: 0.0%
GLPG | $28.905 -0.02% 44K

Health Technology

| -25.19% | O: -1.72% H: 1.8% C: 1.59%
BIIB | $192.68 1.13% 590K

Health Technology

| -13.9% | O: 0.16% H: 0.43% C: -2.76%
AZN | $68.3 -0.09% 2M

Health Technology

| 11.85% | O: 0.28% H: 0.93% C: 0.75%
AMGN | $266.895 1.58% 950K

Health Technology

| -8.79% | O: -0.21% H: 0.34% C: 0.07%
report global protein growth market

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.185 0.19% 430K

Health Technology

| -8.11% | O: 0.14% H: 0.35% C: 0.07%
XNCR | $18.325 -3.3% 220K

Health Technology

| -7.02% | O: -3.56% H: 2.91% C: -3.34%
MOR | $17.96 -0.5% 72K

Health Technology

| 4.15% | O: -0.4% H: 0.23% C: -0.46%
MGNX | $15.42 -4.05% 240K

Health Technology

| -10.16% | O: -5.25% H: 2.94% C: 2.18%
INCY | $52.45 -0.7% 530K

Health Technology

| -8.68% | O: 3.8% H: 1.1% C: -1.17%
financial

Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | $20.2 510

Health Technology

| -1.6% | O: 3.52% H: 0.0% C: -1.18%
AZNCF | $138.24 800

Health Technology

| 12.13% | O: 0.06% H: 2.34% C: 2.29%
ALPMY | $9.47 520K

Manufacturing

| -13.68% | O: 0.37% H: 0.74% C: 0.28%
TAK | News | $13.185 0.19% 430K

Health Technology

| -8.11% | O: 0.14% H: 0.35% C: 0.07%
NVS | $93.81 1.34% 1.2M

Health Technology

| -7.41% | O: -0.34% H: 0.23% C: -1.13%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -7.44% | O: 0.7% H: 0.0% C: 0.0%
GSK | $39.605 0.85% 790K

Health Technology

| -3.58% | O: 1.22% H: 0.07% C: -0.43%
LLY | $728.765 -2.3% 1.5M

Health Technology

| 1.83% | O: -0.96% H: 1.75% C: 1.75%
BMY | $48.58 0.58% 2.6M

Health Technology

| -2.91% | O: -0.18% H: 0.48% C: -1.91%
ABBV | News | $166.43 1.08% 2M

Health Technology

| -4.57% | O: 0.8% H: 0.0% C: 0.0%
ZLAB | News | $14.125 -0.67% 45K

Health Technology

| -25.59% | O: -1.15% H: 1.03% C: -1.5%
VRTX | News | $395.0 0.39% 550K

Health Technology

| -5.63% | O: -0.28% H: 0.49% C: -0.32%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| -1.49% | O: -0.06% H: 0.0% C: 0.0%
IPHA | $2.35 3.6K

Health Technology

| -8.91% | O: -3.1% H: 1.2% C: -0.8%
INCY | $52.45 -0.7% 530K

Health Technology

| -8.68% | O: 3.8% H: 1.1% C: -1.17%
BIIB | $192.68 1.13% 590K

Health Technology

| -20.26% | O: -3.72% H: 0.58% C: -3.82%
AZN | $68.3 -0.09% 2M

Health Technology

| 11.16% | O: -0.26% H: 0.73% C: -0.36%
ARGX | $357.65 -0.21% 93K

Health Technology

| -5.61% | O: -2.3% H: 1.65% C: 0.83%
AMGN | $266.895 1.58% 950K

Health Technology

| -10.02% | O: 0.06% H: 0.31% C: -1.4%
expansion growth market

FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.185 0.19% 430K

Health Technology

| -7.65% | O: 0.07% H: 0.46% C: 0.42%
fda first treatment

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Published: 2024-02-07 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.185 0.19% 430K

Health Technology

| -7.13% | O: 0.07% H: 0.42% C: 0.07%
NBIX M | $131.98 -0.42% 140K

Health Technology

| -6.81% | O: -5.57% H: 6.04% C: 0.96%
financial results

Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 16K

Health Technology

| -13.72% | O: -1.53% H: 0.0% C: 0.0%
AZNCF | $138.24 800

Health Technology

| 1.09% | O: -0.37% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -8.98% | O: 0.41% H: 0.0% C: 0.0%
UCBJY | $63.676 7.2K

Manufacturing

| 37.02% | O: 1.71% H: 1.28% C: 0.94%
ALPMY | $9.47 520K

Manufacturing

| -14.23% | O: 0.28% H: 0.18% C: 0.0%
TAK | News | $13.185 0.19% 430K

Health Technology

| -7.13% | O: 0.07% H: 0.42% C: 0.07%
NVS | $93.81 1.34% 1.2M

Health Technology

| -10.28% | O: 0.09% H: 0.39% C: -0.36%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -6.93% | O: 1.47% H: 0.0% C: 0.0%
LLY | $728.765 -2.3% 1.5M

Health Technology

| 6.49% | O: 0.76% H: 4.31% C: 2.11%
BMY | $48.58 0.58% 2.6M

Health Technology

| -1.95% | O: -0.14% H: 0.35% C: -1.12%
ABBV | News | $166.43 1.08% 2M

Health Technology

| -3.43% | O: 1.48% H: 0.0% C: 0.0%
VRTX | News | $395.0 0.39% 550K

Health Technology

| -5.09% | O: 0.15% H: 2.4% C: 0.56%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| -2.19% | O: 1.33% H: 0.0% C: 0.0%
JAZZ | $110.6 1.22% 210K

Health Technology

| -14.12% | O: -0.02% H: 0.0% C: -1.4%
AZN | $68.3 -0.09% 2M

Health Technology

| 1.83% | O: -0.4% H: 0.19% C: -0.33%
AMGN | $266.895 1.58% 950K

Health Technology

| -16.18% | O: -0.18% H: 0.0% C: -6.22%
report cancer blood growth market

← Previous
1
2
Next →

published : This year symbols : TAK

save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

published : This year symbols : TAK save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

published : This year symbols : TAK

save search